GNAQ and uveal melanoma: T-cell reactions may be triggered by recurrent mutations in the GNAQ and GNA11 genes. Uveal melanoma (UM) may be a desirable target for immunotherapeutic treatments due to the anticipated low immune selective pressure in this condition. Furthermore, researchers speculated that distinct mutations (Q209P or Q209L) may exhibit varying antigenicity and immune system responses.